Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · IEX Real-Time Price · USD
7.33
-0.23 (-3.04%)
At close: Jul 19, 2024, 4:00 PM
7.32
-0.01 (-0.14%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Acrivon Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ACRV stock have an average target of 24, with a low estimate of 17 and a high estimate of 30. The average target predicts an increase of 227.42% from the current stock price of 7.33.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 15, 2024.
Analyst Ratings
The average analyst rating for ACRV stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 3 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 6 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy Reiterates $25 | Buy | Reiterates | $25 | +241.06% | May 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $22 | Strong Buy | Maintains | $20 → $22 | +200.14% | May 14, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 29, 2024 |
| BMO Capital | BMO Capital | Buy Maintains $18 → $25 | Buy | Maintains | $18 → $25 | +241.06% | Apr 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +172.85% | Apr 25, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
450.54K
EPS This Year
-2.53
from -2.74
EPS Next Year
-2.47
from -2.53
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 3.2M | 55.0M | 180.3M | 363.0M |
| Avg | n/a | 450,544 | 21.3M | 67.1M | 146.7M |
| Low | n/a | n/a | n/a | 3.9M | 23.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 12,111.9% | 748.3% | 440.8% |
| Avg | - | - | 4,617.9% | 215.8% | 118.5% |
| Low | - | - | - | -81.6% | -65.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.26 | -1.89 | -1.70 | -1.23 | -1.76 |
| Avg | -2.53 | -2.47 | -2.76 | -2.42 | -3.06 |
| Low | -2.91 | -3.08 | -3.99 | -4.57 | -4.23 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.